Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
A 2022 randomized trial of exenatide did not meet its primary endpoint for reducing heavy drinking days in the overall population, though exploratory analyses suggested potential benefits in participants with obesity
GLP-1 receptor activation can influence autonomic signaling, potentially shifting the balance in ways that reduce the neural drive to salivary glands
Outcomes 15 studies involving 107 patients were assessed which suggested some benefit including potential resolution or reduction in hypoglycaemic episodes and/or symptoms and/or glucose stabilising effects in all cases treated with GLP-1 RMs (Table 2)
Participants receiving efpeglenatide more frequently achieved weight loss of 5% or 10%
Safety, Handling & Reconstitution For optimal solubility and structural stability, researchers must reconstitute the lyophilised solid using Bacteriostatic Reconstitution Solution (0.9% Benzyl Alcohol)
Peak 2024: Compounded GLP-1s captured ~30% of U.S
US$ 21.89
US$ 24.09
US$ 26.54
US$ 25.88
US$ 21.45
US$ 23.18
